CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
急性髓系白血病的免疫治疗策略
英文原题：Immune-Based Therapeutic Strategies for Acute Myeloid Leukemia.
查看英文原题
Immune-Based Therapeutic Strategies for Acute Myeloid Leukemia.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
过去几年，急性髓系白血病（AML）的免疫治疗策略开发与设计日益受到重视，这一趋势受到实体瘤免疫疗法成功的推动。相关策略范围广泛，包括抗体偶联药物；阻断程序性细胞死亡蛋白1（PD-1）、细胞毒性T淋巴细胞相关抗原4（CTLA-4）或T细胞免疫球蛋白和黏蛋白结构域蛋白3（TIM-3）的免疫检查点抑制剂；基于T细胞的单克隆及双特异性T细胞衔接抗体；CAR-T 细胞疗法；以及白血病疫苗。目前有多种药物正在研发，也有多项Ⅰ/Ⅱ期研究开展中。这些试验将帮助加深我们对AML发病机制的认识，并促进确定最佳AML免疫治疗策略。本文讨论免疫治疗的作用机制，并综述现有数据。
展开英文摘要原文
The development and design of immune-based strategies have become an increasingly important topic during the last few years in acute myeloid leukemia (AML), based on successful immunotherapies in solid cancer. The spectrum ranges from antibody drug conjugates, immune checkpoint inhibitors blocking programmed cell death protein 1 (PD1), cytotoxic T lymphocyte antigen 4 (CTLA4) or T cell immunoglobulin and mucin domain containing-3 (TIM3), to T-cell based monoclonal and bispecific T-cell engager antibodies, chimeric antigen receptor-T-cell (CAR-T) approaches and leukemia vaccines.
Currently, there are many substances in development and multiple phase I/II studies are ongoing. These trials will help us to deepen our understanding of the pathogenesis of AML and facilitate the best immunotherapeutic strategy in AML.
We discuss here the mode of action of immune-based therapies and provide an overview of the available data.
论文信息
- 作者
- Böhme M、Kayser S
- 单位
- Medical Clinic and Policlinic I, Hematology and Cellular Therapy, University Hospital Leipzig, 04103 Leipzig, Germany.Germany
- 文献类型
- 综述
- 期刊
- Cancers2021 Dec 27
- 原文标识
- PubMed 35008269 · DOI 10.3390/cancers14010105
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →